Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience

被引：0
|
作者：
Mare, M. [1 ]
Munao, S. [1 ]
Germana, S. [1 ]
Colarossi, C. [1 ]
Sciacca, D. [1 ]
Giuffrida, D. [1 ]
Giannone, G. [1 ]
机构：
[1] Mediterranean Inst Oncol, Div Med Oncol, Viagrande, CT, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
D30
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Nab-paclitaxel in combination with gemcitabine for the treatment of metastatic pancreas cancer: the South Wales experience
    Quinton, A. E.
    Gwynne, S. H.
    Yim, K. L.
    MEDICAL ONCOLOGY, 2018, 35 (08)
  • [32] Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.
    De Vita, Fernando
    Orditura, Michele
    Febbraro, Antonio
    Morgillo, Floriana
    Laterza, Maria Maddalena
    Fabozzl, Alesslo
    Giordano, Guido
    Savastano, Beatrice
    Petrillo, Angelica
    Ventriglia, Joie
    Ciardiello, Fortunato
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china
    Cui, Jiujie
    Zhang, Xiaochen
    Qu, Shuli
    Wang, Liwei
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (04) : 691 - 697
  • [34] Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
    Dorman, Klara
    Boeck, Stefan
    Caca, Karel
    Reichert, Maximilian
    Ettrich, Thomas J.
    Oettle, Helmut
    Waidmann, Oliver
    Modest, Dominik P.
    Mueller, Lothar
    Michl, Patrick
    Kanzler, Stephan
    Pink, Daniel
    Reinacher-Schick, Anke
    Geissler, Michael
    Pelz, Henning
    Kunzmann, Volker
    Held, Swantje
    Schichtl, Thomas
    Heinemann, Volker
    Kullmann, Frank
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (10): : 935 - 943
  • [35] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
    Ozaka, Masato
    Sasaki, Takashi
    Yamada, Ikuhiro
    Kanata, Ryo
    Akiyama, Dai
    Katagiri, Tomoko
    Takano, Koichi
    Matsuyama, Masato
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [36] A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study
    Nakazawa, J.
    Otsuka, T.
    Shimokawa, M.
    Koga, F.
    Ueda, Y.
    Otsu, S.
    Arima, S.
    Fukahori, M.
    Makiyama, A.
    Taguchi, H.
    Honda, T.
    Shibuki, T.
    Shirakawa, T.
    Mitsugi, K.
    Nio, K.
    Ide, Y.
    Ureshino, N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Vitamin D receptor agonist paricalcitol plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
    Perez, Kimberly
    Cleary, James M.
    Karasic, Thomas Benjamin
    Raghavan, Srivatsan
    Rahma, Osama E.
    Nowak, Jonathan
    Borazanci, Erkut Hasan
    Downes, Michael
    Drebin, Jeffrey A.
    Tuveson, David A.
    Ting, David Tsai
    Moffitt, Richard
    Yeh, Jen Jen
    Aguirre, Andrew
    Evans, Ronald
    Von Hoff, Daniel D.
    Odwyer, Peter J.
    Wolpin, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [38] Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
    Rapposelli, Ilario Giovanni
    Casadei-Gardini, Andrea
    Vivaldi, Caterina
    Bartolini, Giulia
    Bernardini, Laura
    Passardi, Alessandro
    Frassineti, Giovanni Luca
    Massa, Valentina
    Cucchetti, Alessandro
    BIOMOLECULES, 2021, 11 (06)
  • [39] Retrospective analysis of institutional outcomes with FOLFIRINOX versus nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
    Singh, Amisha
    Shroff, Rachna T.
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [40] FOLFIRINOX versus gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: a single-center cohort study
    Cho, I.
    Kang, H.
    Jo, J.
    Lee, H.
    Chung, M.
    Park, J.
    Park, S.
    Song, S.
    Park, M.
    An, C.
    Jung, S.
    Bang, S.
    ANNALS OF ONCOLOGY, 2018, 29
12345